Citations (128)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Viola Trevisani, Lorenzo Iughetti, Laura Lucaccioni & Barbara Predieri. (2023) Endocrine immune-related adverse effects of immune-checkpoint inhibitors. Expert Review of Endocrinology & Metabolism 0:0, pages 1-11.
Read now
Read now
Farheen Manji, Rob C Laister & John Kuruvilla. (2022) An evaluation of pembrolizumab for classical Hodgkin lymphoma. Expert Review of Hematology 15:4, pages 285-293.
Read now
Read now
Christian Borgo, Claudio D’Amore, Luca Cesaro, Stefania Sarno, Lorenzo A. Pinna, Maria Ruzzene & Mauro Salvi. (2021) How can a traffic light properly work if it is always green? The paradox of CK2 signaling. Critical Reviews in Biochemistry and Molecular Biology 56:4, pages 321-359.
Read now
Read now
Gulidanna Shayan, Raghvendra Srivastava, Jing Li, Nicole Schmitt, Lawrence P. Kane & Robert L. Ferris. (2017) Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. OncoImmunology 6:1.
Read now
Read now
Thilipan Thaventhiran, Naif Alhumeed, Han XA Yeang, Swaminathan Sethu, Jocelyn S Downey, Ahmad F Alghanem, Adedamola Olayanju, Emma L Smith, Michael J Cross, Steven D Webb, Dominic P Williams, Adrian Bristow, Christina Ball, Richard Stebbings & Jean G Sathish. (2014) Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist. mAbs 6:5, pages 1290-1299.
Read now
Read now
Articles from other publishers (123)
Alan T. Yeo, Rushil Shah, Konstantinos Aliazis, Rinku Pal, Tuoye Xu, Piyan Zhang, Shruti Rawal, Christopher M. Rose, Frederick S. Varn, Vicky A. Appleman, Joon Yoon, Hemant Varma, Steven P. Gygi, Roel G.W. Verhaak, Vassiliki A. Boussiotis & Al Charest. (2023) Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma. Cancer Immunology Research 11:5, pages 629-645.
Crossref
Crossref
Marc C. Pulanco, Anne T. Madsen, Ankit Tanwar, Devin T. Corrigan & Xingxing Zang. (2023) Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. Cellular & Molecular Immunology 20:7, pages 694-713.
Crossref
Crossref
Shannon A. Carty, Carlos A. Murga-Zamalloa & Ryan A. Wilcox. (2023) SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Crossref
Mateusz Kciuk, Damian Kołat, Żaneta Kałuzińska-Kołat, Mateusz Gawrysiak, Rafał Drozda, Ismail Celik & Renata Kontek. (2023) PD-1/PD-L1 and DNA Damage Response in Cancer. Cells 12:4, pages 530.
Crossref
Crossref
Annoor Awadasseid, Yongnan Zhou, Koutian Zhang, Kaiming Tian, Yanling Wu & Wen Zhang. (2023) Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. Biomedicine & Pharmacotherapy 157, pages 114057.
Crossref
Crossref
Shimeng Zhou, Jinfeng Zhu, Jingwei Xu, Bingzi Gu, Qiao Zhao, Congzhou Luo, Zhoufeng Gao, Y. Eugene Chin & Xiaju Cheng. (2022)
Anti‐tumour potential of
PD‐L1
/
PD
‐1 post‐translational modifications
. Immunology 167:4, pages 471-481.
Crossref
Crossref
Jianheng Luo, Ke Liu, Yong Wang & Hongge Li. (2022) Divergent roles of PD-L1 in immune regulation during ischemia–reperfusion injury. Frontiers in Immunology 13.
Crossref
Crossref
Faisal K. Alkholifi & Rana M. Alsaffar. (2022) Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. Medicina 58:11, pages 1572.
Crossref
Crossref
Stephanie Laba, Grace Mallett & Shoba Amarnath. (2022) The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells. Seminars in Cancer Biology 86, pages 1045-1055.
Crossref
Crossref
Yunyun Huang & Rudolf Winklbauer. (2022) Cell cortex regulation by the planar cell polarity protein Prickle1. Journal of Cell Biology 221:7.
Crossref
Crossref
Shugo Sakihama & Kennosuke Karube. (2022) Genetic Alterations in Adult T-Cell Leukemia/Lymphoma: Novel Discoveries with Clinical and Biological Significance. Cancers 14:10, pages 2394.
Crossref
Crossref
Hao Dong, Yihang Qi, Xiangyi Kong, Zhongzhao Wang, Yi Fang & Jing Wang. (2022) PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Frontiers in Pharmacology 13.
Crossref
Crossref
Mengling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang & Yong Xia. (2022) Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Xingcheng Yang, Ling Ma, Xiaoying Zhang, Liang Huang & Jia Wei. (2022) Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Seyed Z. Rasihashemi, Erfan Rezazadeh Gavgani, Reza Majidazar, Parya Seraji, Mobina Oladghaffari, Tohid Kazemi & Parisa Lotfinejad. (2021) Tumor‐derived exosomal PD‐L1 in progression of cancer and immunotherapy. Journal of Cellular Physiology 237:3, pages 1648-1660.
Crossref
Crossref
Patrycja Wińska, Łukasz Widło, Elżbieta Senkara, Mirosława Koronkiewicz, Jarosław M. Cieśla, Alicja Krzyśko, Katarzyna Skierka & Joanna Cieśla. (2022) Inhibition of Protein Kinase CK2 Affects Thymidylate Synthesis Cycle Enzyme Level and Distribution in Human Cancer Cells. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Yuwei Hao & Matthew C. Cook. (2022) Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. Frontiers in Immunology 12.
Crossref
Crossref
Andriani Charalambous & Mark-Alexander Schwarzbich. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
42
.
Liansha Tang, Jialing Wang, Nan Lin, Yuwen Zhou, Wenbo He, Jiyan Liu & Xuelei Ma. (2021) Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. Frontiers in Immunology 12.
Crossref
Crossref
Yan Mi, Jinming Han, Jie Zhu & Tao Jin. (2021) Role of the PD‐1/PD‐L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. Molecular Neurobiology 58:12, pages 6249-6271.
Crossref
Crossref
Juhi R. Kuchroo, David A. Hafler, Arlene H. Sharpe & Liliana E. Lucca. (2021) The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology 6:65.
Crossref
Crossref
Gustav van Niekerk, Michelle van der Merwe & Anna‐Mart Engelbrecht. (2021) Diabetes and susceptibility to infections: Implication for COVID‐19. Immunology 164:3, pages 467-475.
Crossref
Crossref
Céline Pisibon, Amira Ouertani, Corine Bertolotto, Robert Ballotti & Yann Cheli. (2021) Immune Checkpoints in Cancers: From Signaling to the Clinic. Cancers 13:18, pages 4573.
Crossref
Crossref
Mohammad Jalili-Nik, Arash Soltani, Baratali Mashkani, Houshang Rafatpanah & Seyed Isaac Hashemy. (2021) PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. International Immunopharmacology 98, pages 107870.
Crossref
Crossref
Vaibhavkumar S. Gawali, Ameet A. Chimote, Hannah S. Newton, Manuel G. Feria-Garzón, Martina Chirra, Edith M. Janssen, Trisha M. Wise-Draper & Laura Conforti. (2021) Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients. Frontiers in Pharmacology 12.
Crossref
Crossref
Konrad Chojnacki, Patrycja Wińska, Olena Karatsai, Mirosława Koronkiewicz, Małgorzata Milner-Krawczyk, Monika Wielechowska, Maria Jolanta Rędowicz, Maria Bretner & Paweł Borowiecki. (2021) Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1H-benzimidazol-1-yl)propan-1-ols—Intracellular TBBi-Based CK2 Inhibitors with Proapoptotic Properties. International Journal of Molecular Sciences 22:12, pages 6261.
Crossref
Crossref
Jun-Nan Guo, Bai-Rong Xia, Shen-Hui Deng, Chang Yang, Ya-Nan Pi, Bin-Bin Cui & Wei-Lin Jin. (2021) Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Abolfazl Maghrouni, Maryam Givari, Mohammad Jalili-Nik, Hamid Mollazadeh, Bahram Bibak, Mohammad Montazami Sadeghi, Amir R. Afshari, Thomas P. Johnston & Amirhossein Sahebkar. (2021) Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. International Immunopharmacology 93, pages 107403.
Crossref
Crossref
Zhenglei Wang, Riguo Lan, Yuanyuan Xu, Jiakun Zuo, Xiangan Han, Vanhnaseng Phouthapane, Zhenhua Luo & Jinfeng Miao. (2021) Taurine Alleviates Streptococcus uberis-Induced Inflammation by Activating Autophagy in Mammary Epithelial Cells. Frontiers in Immunology 12.
Crossref
Crossref
Mengke Niu, Ming Yi, Ning Li, Suxia Luo & Kongming Wu. (2021) Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Experimental Hematology & Oncology 10:1.
Crossref
Crossref
Catherine L. Tan, Juhi R. Kuchroo, Peter T. Sage, Dan Liang, Loise M. Francisco, Jessica Buck, Youg Raj Thaker, Qianxia Zhang, Shannon L. McArdel, Vikram R. Juneja, Sun Jung Lee, Scott B. Lovitch, Christine Lian, George F. Murphy, Bruce R. Blazar, Dario A.A. Vignali, Gordon J. Freeman & Arlene H. Sharpe. (2021) PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. Journal of Experimental Medicine 218:1.
Crossref
Crossref
Zhixuan Song & Yimiao Lin. (2021) Innovative immunotherapy targeting at PD-1/PD-L1 signaling pathway: mechanism, efficacy and safety analysis of monotherapy and combination therapies in non-small cell lung cancer (NSCLC) treatment. E3S Web of Conferences 267, pages 02026.
Crossref
Crossref
Gustav van Niekerk, Angus G. Dalgleish, Fourie Joubert, Annie Joubert & Anna-Mart Engelbrecht. (2021) The immuno-oncological implications of insulin. Life Sciences 264, pages 118716.
Crossref
Crossref
Marzia Del Re, Ron H.N. van Schaik, Stefano Fogli, Ron H.J. Mathijssen, Federico Cucchiara, Annalisa Capuano, Cristina Scavone, Guido W. Jenster & Romano Danesi. (2021) Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875:1, pages 188463.
Crossref
Crossref
Anna S. Tocheva, Michael Peled, Marianne Strazza, Kieran R. Adam, Shalom Lerrer, Shruti Nayak, Inbar Azoulay-Alfaguter, Connor J.R. Foster, Elliot A. Philips, Benjamin G. Neel, Beatrix Ueberheide & Adam Mor. (2020) Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. Journal of Biological Chemistry 295:52, pages 18036-18050.
Crossref
Crossref
Kevinn Eddy & Suzie Chen. (2020) Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences 21:23, pages 8984.
Crossref
Crossref
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, Yuxiang Fu & Guixiang Liao. (2020) Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. Frontiers in Immunology 11.
Crossref
Crossref
Nikolaos Patsoukis, Qi Wang, Laura StraussVassiliki A. Boussiotis. (2020) Revisiting the PD-1 pathway. Science Advances 6:38.
Crossref
Crossref
Rachel Ambler, Grace L. Edmunds, Sin Lih TanSilvia CirilloJane I. Pernes, Xiongtao Ruan, Jorge Huete-Carrasco, Carissa C. W. WongJiahe Lu, Juma Ward, Giulia TotiAlan J. HedgesSimon J. Dovedi, Robert F. Murphy, David J. Morgan & Christoph Wülfing. (2020) PD-1 suppresses the maintenance of cell couples between cytotoxic T cells and target tumor cells within the tumor. Science Signaling 13:649.
Crossref
Crossref
Lei Liu, Qin Wang, Zhilin Qiu, Yujuan Kang, Jiena Liu, Shipeng Ning, Yanling Yin, Da Pang & Shouping Xu. (2020) Noncoding RNAs: the shot callers in tumor immune escape. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Xiaozheng Xu, Bowen Hou, Amitkumar Fulzele, Takeya Masubuchi, Yunlong Zhao, Zijun Wu, Yanyan Hu, Yong Jiang, Yanzhe Ma, Haopeng Wang, Eric J. Bennett, Guo Fu & Enfu Hui. (2020) PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. Journal of Cell Biology 219:6.
Crossref
Crossref
Luisa Chocarro de Erauso, Miren Zuazo, Hugo Arasanz, Ana Bocanegra, Carlos Hernandez, Gonzalo Fernandez, Maria Jesus Garcia-Granda, Ester Blanco, Ruth Vera, Grazyna Kochan & David Escors. (2020) Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. Frontiers in Pharmacology 11.
Crossref
Crossref
Carlos A Murga-Zamalloa, Noah A. Brown & Ryan A. Wilcox. (2020) Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas. Journal of Clinical Pathology 73:4, pages 197-203.
Crossref
Crossref
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila & José Antonio Gil‐Montoya. (2019) An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. Oral Diseases 26:3, pages 511-526.
Crossref
Crossref
Ying-xu Shi, Yan-ji He, Yong Zhou, Hao-ke Li, Dan Yang, Ren-yan Li, Zhong-liang Deng & Yan-fei Gao. (2020) LSD1 negatively regulates autophagy in myoblast cells by driving PTEN degradation. Biochemical and Biophysical Research Communications 522:4, pages 924-930.
Crossref
Crossref
Anja Wessely, Theresa Steeb, Michael Erdmann, Lucie Heinzerling, Julio Vera, Max Schlaak, Carola Berking & Markus Vincent Heppt. (2020) The Role of Immune Checkpoint Blockade in Uveal Melanoma. International Journal of Molecular Sciences 21:3, pages 879.
Crossref
Crossref
Estefania Alcaraz, Jordi Vilardell, Christian Borgo, Eduard Sarró, Maria Plana, Oriano Marin, Lorenzo A. Pinna, José R. Bayascas, Anna Meseguer, Mauro Salvi, Emilio Itarte & Maria Ruzzene. (2020) Effects of CK2β subunit down-regulation on Akt signalling in HK-2 renal cells. PLOS ONE 15:1, pages e0227340.
Crossref
Crossref
Luoyan Ai, Antao Xu & Jie Xu. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
33
59
.
Yiting Wang, Ping Wang & Jie Xu. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
347
398
.
Jesús Ogando, María Eugenia Sáez, Javier Santos, Cristina Nuevo-Tapioles, Marta Gut, Anna Esteve-Codina, Simon Heath, Antonio González-Pérez, José M. Cuezva, Rosa Ana Lacalle & Santos Mañes. (2019) PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Junshang Ge, Bo Xiang, Xu Wu, Jian Ma, Ming Zhou, Xiaoling Li, Yong Li, Guiyuan Li, Wei Xiong, Can Guo & Zhaoyang Zeng. (2019) Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Molecular Cancer 18:1.
Crossref
Crossref
Youg Raj Thaker, Monika Raab, Klaus Strebhardt & Christopher E. Rudd. (2019) GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity. Nature Communications 10:1.
Crossref
Crossref
Geny Piro, Carmine Carbone, Luisa Carbognin, Sara Pilotto, Chiara Ciccarese, Roberto Iacovelli, Michele Milella, Emilio Bria & Giampaolo Tortora. (2019) Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. Cancers 11:10, pages 1525.
Crossref
Crossref
Weiting Qin, Lipeng Hu, Xueli Zhang, Shuheng Jiang, Jun Li, Zhigang Zhang & Xu Wang. (2019) The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Frontiers in Immunology 10.
Crossref
Crossref
David A. Horwitz, Tarek M. Fahmy, Ciriaco A. Piccirillo & Antonio La Cava. (2019) Rebalancing Immune Homeostasis to Treat Autoimmune Diseases. Trends in Immunology 40:10, pages 888-908.
Crossref
Crossref
Atefeh Ghahremanloo, Arash Soltani, Seyed Mohamad Sadegh Modaresi & Seyed Isaac Hashemy. (2019) Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology 42:5, pages 609-626.
Crossref
Crossref
Arash Salmaninejad, Saeed Farajzadeh Valilou, Arezoo Gowhari Shabgah, Saeed Aslani, Malihe Alimardani, Alireza Pasdar & Amirhossein Sahebkar. (2019) PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy. Journal of Cellular Physiology 234:10, pages 16824-16837.
Crossref
Crossref
Li Wang, Deze Zhao, Kang Qin, Faisal UL Rehman & Xiaochun Zhang. (2019) Effect and biomarker of Nivolumab for non–small-cell lung cancer. Biomedicine & Pharmacotherapy 117, pages 109199.
Crossref
Crossref
Anna C. Beielstein & Christian P. Pallasch. (2019) Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy. International Journal of Molecular Sciences 20:17, pages 4158.
Crossref
Crossref
Craig Fenwick, Juan-Luis Loredo-Varela, Victor Joo, Céline Pellaton, Alex Farina, Navina Rajah, Line Esteves-Leuenberger, Thibaut Decaillon, Madeleine Suffiotti, Alessandra Noto, Khalid Ohmiti, Raphael Gottardo, Winfried Weissenhorn & Giuseppe Pantaleo. (2019) Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway. Journal of Experimental Medicine 216:7, pages 1525-1541.
Crossref
Crossref
Vijay Kumar. (2018) Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting. Inflammation 42:3, pages 765-788.
Crossref
Crossref
Gaëlle Noé, Audrey Bellesoeur, Lisa Golmard, Audrey Thomas-Schoemann, Pascaline Boudou-Rouquette, Manuela Tiako Meyo, Alicja Puszkiel, Jennifer Arrondeau, Jérome Alexandre, François Goldwasser, Benoit Blanchet & Michel Vidal. (2019) Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Cancers 11:6, pages 762.
Crossref
Crossref
Dana M. Previte, Christina P. Martins, Erin C. O’Connor, Meghan L. Marre, Gina M. Coudriet, Noah W. Beck, Ashley V. Menk, Rebecca H. Wright, Hubert M. Tse, Greg M. Delgoffe & Jon D. Piganelli. (2019) Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4+ T Cells. Cell Reports 27:1, pages 129-141.e4.
Crossref
Crossref
Emily Hays & Benjamin Bonavida. (2019) YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resistance Updates 43, pages 10-28.
Crossref
Crossref
Fatemeh K. Dermani, Pouria Samadi, Golebagh Rahmani, Alisa K. Kohlan & Rezvan Najafi. (2018) PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy. Journal of Cellular Physiology 234:2, pages 1313-1325.
Crossref
Crossref
Maria E. Joosse, Iris Nederlof, Lucy S.K. Walker & Janneke N. Samsom. (2019) Tipping the balance: inhibitory checkpoints in intestinal homeostasis. Mucosal Immunology 12:1, pages 21-35.
Crossref
Crossref
Caroline E. Nunes-Xavier, Javier C. Angulo, Rafael Pulido & José I. López. (2019) A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Current Urology Reports 20:1.
Crossref
Crossref
Shuhei Ogawa & Ryo Abe. 2019. Co-signal Molecules in T Cell Activation. Co-signal Molecules in T Cell Activation
85
133
.
Shigenori Nagai & Miyuki Azuma. 2019. Co-signal Molecules in T Cell Activation. Co-signal Molecules in T Cell Activation
25
51
.
Qianquan Ma, Wenyong Long, Changsheng Xing, Junjun Chu, Mei Luo, Helen Y. Wang, Qing Liu & Rong-Fu Wang. (2018) Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. Frontiers in Immunology 9.
Crossref
Crossref
Prabhakaran Kumar, Palash Bhattacharya & Bellur S. Prabhakar. (2018) A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. Journal of Autoimmunity 95, pages 77-99.
Crossref
Crossref
Emilie Soularue, Patricia Lepage, Jean Frederic Colombel, Clelia Coutzac, David Faleck, Lysiane Marthey, Michael Collins, Nathalie Chaput, Caroline Robert & Franck Carbonnel. (2018) Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 67:11, pages 2056-2067.
Crossref
Crossref
Penelope A. Morel. (2018)
Differential
T
‐cell receptor signals for T helper cell programming
. Immunology 155:1, pages 63-71.
Crossref
Crossref
Yue Wang, Qing Li, Lin Zhou, Xuping Ding & Liming Lu. (2018) Peptide Tk-PQ induces immunosuppression in skin allogeneic transplantation via increasing Foxp3+ Treg and impeding nuclear translocation of NF-κB. Molecular Immunology 101, pages 597-607.
Crossref
Crossref
Chien-Yu Chen, Jingyu Chen, Lina He & Bangyan L. Stiles. (2018) PTEN: Tumor Suppressor and Metabolic Regulator. Frontiers in Endocrinology 9.
Crossref
Crossref
Ee Lyn Lim, Fiorella M. Cugliandolo, Dalya R. Rosner, David Gyori, Rahul Roychoudhuri & Klaus Okkenhaug. (2018) Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. JCI Insight 3:11.
Crossref
Crossref
Xiaoxiao Wang, Xin Cao, Ruifang Sun, Charlene Tang, Alexandar Tzankov, Jun Zhang, Ganiraju C. Manyam, Min Xiao, Yi Miao, Kausar Jabbar, Xiaohong Tan, Yuyang Pang, Carlo Visco, Yan Xie, Karen Dybkaer, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, J. Han van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Ben M. Parsons, Jane N. Winter, Miguel A. Piris, Shaoying Li, Roberto N. Miranda, L. Jeffrey Medeiros, Yong Li, Zijun Y. Xu-Monette & Ken H. Young. (2018) Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia 20:6, pages 574-593.
Crossref
Crossref
Mark A. Samaan, Polychronis Pavlidis, Sophie Papa, Nick Powell & Peter M. Irving. (2018) Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nature Reviews Gastroenterology & Hepatology 15:4, pages 222-234.
Crossref
Crossref
Anthousa Kythreotou, Abdul Siddique, Francesco A Mauri, Mark Bower & David J Pinato. (2018) PD-L1. Journal of Clinical Pathology 71:3, pages 189-194.
Crossref
Crossref
Antoine Marçais & Thierry Walzer. (2018) An immunosuppressive pathway for tumor progression. Nature Medicine 24:3, pages 260-261.
Crossref
Crossref
Martin W. LaFleur, Yuki Muroyama, Charles G. Drake & Arlene H. Sharpe. (2018) Inhibitors of the PD-1 Pathway in Tumor Therapy. The Journal of Immunology 200:2, pages 375-383.
Crossref
Crossref
Ayaka Sugiura & Jeffrey C. Rathmell. (2018) Metabolic Barriers to T Cell Function in Tumors. The Journal of Immunology 200:2, pages 400-407.
Crossref
Crossref
Jie Bai, Zhitao Gao, Xiang Li, Liang Dong, Weidong Han & Jing Nie. (2017) Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget 8:66, pages 110693-110707.
Crossref
Crossref
Tim Wartewig, Zsuzsanna Kurgyis, Selina Keppler, Konstanze Pechloff, Erik Hameister, Rupert Öllinger, Roman Maresch, Thorsten Buch, Katja Steiger, Christof Winter, Roland Rad & Jürgen Ruland. (2017) PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552:7683, pages 121-125.
Crossref
Crossref
Zijun Y. Xu-Monette, Mingzhi Zhang, Jianyong Li & Ken H. Young. (2017) PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology 8.
Crossref
Crossref
Robert W. Figliozzi, Feng Chen & S. Victor Hsia. (2017) New insights on thyroid hormone mediated regulation of herpesvirus infections. Cell & Bioscience 7:1.
Crossref
Crossref
Ying Zhang, Raj Kurupati, Ling Liu, Xiang Yang Zhou, Gao Zhang, Abeer Hudaihed, Flavia Filisio, Wynetta Giles-Davis, Xiaowei Xu, Giorgos C. Karakousis, Lynn M. Schuchter, Wei Xu, Ravi Amaravadi, Min Xiao, Norah Sadek, Clemens Krepler, Meenhard Herlyn, Gordon J. Freeman, Joshua D. Rabinowitz & Hildegund C.J. Ertl. (2017) Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell 32:3, pages 377-391.e9.
Crossref
Crossref
Hugo Arasanz, Maria Gato-Cañas, Miren Zuazo, Maria Ibañez-Vea, Karine Breckpot, Grazyna Kochan & David Escors. (2017) PD1 signal transduction pathways in T cells. Oncotarget 8:31, pages 51936-51945.
Crossref
Crossref
Chandrika Gowda, Mario Soliman, Malika Kapadia, Yali Ding, Kimberly Payne & Sinisa Dovat. (2017) Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia. Advances in Biological Regulation 65, pages 16-25.
Crossref
Crossref
S T Ribeiro, M Tesio, J C Ribot, E Macintyre, J T Barata & B Silva-Santos. (2016) Casein kinase 2 controls the survival of normal thymic and leukemic γδ T cells via promotion of AKT signaling. Leukemia 31:7, pages 1603-1610.
Crossref
Crossref
Peter J. Siska, Kathryn E. Beckermann, Frank M. Mason, Gabriela Andrejeva, Allison R. Greenplate, Adam B. Sendor, Yun-Chen J. Chiang, Armando L. Corona, Lelisa F. Gemta, Benjamin G. Vincent, Richard C. Wang, Bumki Kim, Jiyong Hong, Chiu-lan Chen, Timothy N. Bullock, Jonathan M. Irish, W. Kimryn Rathmell & Jeffrey C. Rathmell. (2017) Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight 2:12.
Crossref
Crossref
Andrew Brandmaier, Sheng-Qi Hou, Sandra Demaria, Silvia C. Formenti & Wen H. Shen. (2017) PTEN at the interface of immune tolerance and tumor suppression. Frontiers in Biology 12:3, pages 163-174.
Crossref
Crossref
Maria Ruzzene, Jessika Bertacchini, Alex Toker & Sandra Marmiroli. (2017) Cross-talk between the CK2 and AKT signaling pathways in cancer. Advances in Biological Regulation 64, pages 1-8.
Crossref
Crossref
Seema Gupta, Amrita Roy & Bilikere S. Dwarakanath. (2017) Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. Frontiers in Oncology 7.
Crossref
Crossref
Nikolaos Patsoukis, Jessica D. Weaver, Laura Strauss, Christoph Herbel, Pankaj Seth & Vassiliki A. Boussiotis. (2017) Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses. Frontiers in Immunology 8.
Crossref
Crossref
Rachel Piddock, Kristian Bowles & Stuart Rushworth. (2017) The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. Cancers 9:12, pages 29.
Crossref
Crossref
Teresa Nuñez de Villavicencio-Diaz, Adam Rabalski & David Litchfield. (2017) Protein Kinase CK2: Intricate Relationships within Regulatory Cellular Networks. Pharmaceuticals 10:4, pages 27.
Crossref
Crossref
Lindsay C. Davies, Nina Heldring, Nadir Kadri & Katarina Le Blanc. (2017) Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. Stem Cells 35:3, pages 766-776.
Crossref
Crossref
Michael J. Allegrezza & Jose R. Conejo-Garcia. (2017) Targeted Therapy and Immunosuppression in the Tumor Microenvironment. Trends in Cancer 3:1, pages 19-27.
Crossref
Crossref
Kankana Bardhan, Theodora Anagnostou & Vassiliki A. Boussiotis. (2016) The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology 7.
Crossref
Crossref
Vassiliki A. Boussiotis. (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. New England Journal of Medicine 375:18, pages 1767-1778.
Crossref
Crossref
Peter J. Siska, Gerritje J. W. van der Windt, Rigel J. Kishton, Sivan Cohen, William Eisner, Nancie J. MacIver, Arnon P. Kater, J. Brice Weinberg & Jeffrey C. Rathmell. (2016) Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. The Journal of Immunology 197:6, pages 2532-2540.
Crossref
Crossref
Florian Thuma, Sarah Heiler, Martina Schnölzer & Margot Zöller. (2016)
Palmitoylated claudin7 captured in glycolipid-enriched membrane microdomains promotes metastasis
via
associated transmembrane and cytosolic molecules
. Oncotarget 7:21, pages 30659-30677.
Crossref
Crossref
Frank A. Schildberg, Sarah R. Klein, Gordon J. Freeman & Arlene H. Sharpe. (2016) Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 44:5, pages 955-972.
Crossref
Crossref
Yi Xia, L. Jeffrey Medeiros & Ken H. Young. (2016) Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1865:1, pages 58-71.
Crossref
Crossref
Hesham Soliman, Vongai NyamandiMarysol Garcia-PatinoJulia Nogueira VarelaGirish BankarGuorong LinZhengping Jia & Kathleen M. MacLeod. (2015) Partial deletion of ROCK2 protects mice from high-fat diet-induced cardiac insulin resistance and contractile dysfunction. American Journal of Physiology-Heart and Circulatory Physiology 309:1, pages H70-H81.
Crossref
Crossref
Yan Wang & Melitta Schachner. (2015)
The intracellular domain of L1CAM binds to casein kinase 2α and is neuroprotective
via
inhibition of the tumor suppressors PTEN and p53
. Journal of Neurochemistry 133:6, pages 828-843.
Crossref
Crossref
Rita Fragoso & João T. Barata. (2015) Kinases, tails and more: Regulation of PTEN function by phosphorylation. Methods 77-78, pages 75-81.
Crossref
Crossref
Peter J. Siska & Jeffrey C. Rathmell. (2015) T cell metabolic fitness in antitumor immunity. Trends in Immunology 36:4, pages 257-264.
Crossref
Crossref
Souvik Kar, Amir Samii & Helmut Bertalanffy. (2014) PTEN/PI3K/Akt/VEGF signaling and the cross talk to KRIT1, CCM2, and PDCD10 proteins in cerebral cavernous malformations. Neurosurgical Review 38:2, pages 229-237.
Crossref
Crossref
Nikolaos Patsoukis, Kankana Bardhan, Pranam Chatterjee, Duygu Sari, Bianling Liu, Lauren N. Bell, Edward D. Karoly, Gordon J. Freeman, Victoria Petkova, Pankaj Seth, Lequn Li & Vassiliki A. Boussiotis. (2015) PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nature Communications 6:1.
Crossref
Crossref
Sérgio T. Ribeiro, Julie C. Ribot & Bruno Silva-Santos. (2015) Five Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation. Frontiers in Immunology 6.
Crossref
Crossref
Cristina Girardi & Maria Ruzzene. 2015. Protein Kinase CK2 Cellular Function in Normal and Disease States. Protein Kinase CK2 Cellular Function in Normal and Disease States
125
140
.
Khalil Ahmed, Gretchen Unger, Betsy T. Kren & Janeen H. Trembley. 2015. Protein Kinase CK2 Cellular Function in Normal and Disease States. Protein Kinase CK2 Cellular Function in Normal and Disease States
299
315
.
Akari Minami, Atsuko Nakanishi, Yasunori Ogura, Yasuko Kitagishi & Satoru Matsuda. (2014) Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair. Frontiers in Oncology 4.
Crossref
Crossref
Matthew M. Staron, Simon M. Gray, Heather D. Marshall, Ian A. Parish, Jonathan H. Chen, Curtis J. Perry, Guoliang Cui, Ming O. Li & Susan M. Kaech. (2014) The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection. Immunity 41:5, pages 802-814.
Crossref
Crossref
G. Kenneth Gray, Braden C. McFarland, Amber L. Rowse, Sara A. Gibson & Etty N. Benveniste. (2014) Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells. Oncotarget 5:15, pages 6484-6496.
Crossref
Crossref
Robert Parker, Roderick Clifton-Bligh & Mark P. Molloy. (2014) Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition. Molecular Cancer Therapeutics 13:7, pages 1894-1906.
Crossref
Crossref
Sheng Yao & Lieping Chen. (2014) PD-1 as an Immune Modulatory Receptor. The Cancer Journal 20:4, pages 262-264.
Crossref
Crossref
Vassiliki A. Boussiotis, Pranam Chatterjee & Lequn Li. (2014) Biochemical Signaling of PD-1 on T Cells and Its Functional Implications. The Cancer Journal 20:4, pages 265-271.
Crossref
Crossref
Carolyn A. WorbyJack E. Dixon. (2014) PTEN. Annual Review of Biochemistry 83:1, pages 641-669.
Crossref
Crossref
Benjamin D. Hopkins, Cindy Hodakoski, Douglas Barrows, Sarah M. Mense & Ramon E. Parsons. (2014) PTEN function: the long and the short of it. Trends in Biochemical Sciences 39:4, pages 183-190.
Crossref
Crossref
Cristina CristofolettiMaria Cristina PicchioCristina Lazzeri, Valeria ToccoElena PaganiAntonella BresinBarbara ManciniFrancesca PassarelliAntonio FacchianoEnrico ScalaGiuseppe Alfonso LombardoMaria Cantonetti, Elisabetta CapriniGiandomenico RussoMaria Grazia Narducci. (2013) Comprehensive analysis of PTEN status in Sézary syndrome. Blood 122:20, pages 3511-3520.
Crossref
Crossref